The role of nitric oxide in Doxorubicin-induced cardiotoxicity: experimental study

• Published in: Turkish journal of haematology 2014-03, Vol.31 (1), p.68-74
• Main Authors: Bahadır, Ayşenur, Kurucu, Nilgün, Kadıoğlu, Mine, Yenilme, Engin
• Format: Article
• Language: English
• Subjects: doxorubicin; nitric oxide; nitric oxide synthase inhibitors
• ISSN: 1300-7777; 1308-5263
• DOI: 10.4274/Tjh.2013.0013

We evaluated the myocardial damage in rats treated with doxorubicin (DOX) alone and in combination with nitric oxide synthase (NOS) inhibitors. Twenty-four male Sprague Dawley rats (12 weeks old, weighing 262±18 g) were randomly assigned into 4 groups (n=6). Group I was the control group. In Group II, rats were treated with intraperitoneal (ip) injections of 3 mg/kg DOX once a week for 5 weeks. In Group III, rats received weekly ip injections of 30 mg/kg L-NAME (nonspecific NOS inhibitor) 30 min before DOX injections for 5 weeks. In Group IV, rats received weekly ip injections of 3 mg/kg L-NIL (inducible NOS inhibitor) 30 min before DOX injections for 5 weeks. Rats were weighed 2 times a week. At the end of 6 weeks, hearts were excised and then fixed for light and electron microscopy evaluation and tissue lipid peroxidation (malondialdehyde). Blood samples were also obtained for measuring plasma lipid peroxidation. Weight loss was observed in Group II, Group III, and Group IV. Weight loss was statistically significant in the DOX group. Findings of myocardial damage were significantly higher in animals treated with DOX only than in the control group. Histopathological findings of cardiotoxicity in rats treated with DOX in combination with L-NAME and L-NIL were not significantly different compared with the control group. The level of plasma malondialdehyde in the DOX group (9.3±3.4 µmol/L) was higher than those of all other groups. Our results showed that DOX cardiotoxicity was significantly decreased when DOX was given with NO synthase inhibitors.